Goal: 08 - İnsana Yakışır İş ve Ekonomik Büyüme
Loading...
Description
İnsana Yakışır İş ve Ekonomik Büyüme
İstikrarlı, kapsayıcı ve sürdürülebilir ekonomik büyümeyi, tam ve üretken istihdamı ve herkes için insana yakışır işleri desteklemek
4 results
Publication Search Results
Now showing 1 - 4 of 4
Publication Open Access Time Series Analysis of the Microbiota of Children Suffering From Acute Infectious Diarrhea and Their Recovery After Treatment(2018-06-12) Dinleyici, Ener C.; MARTINEZ-MARTINEZ, Daniel; KARA, ATEŞ; KARBUZ, Adem; DALGIC, Nazan; METIN, Ozge; YAZAR, Ahmet S.; GUVEN, Sirin; Kurugol, Zafer; Turel, Ozden; KUCUKKOC, Mehmet; YASA, Olcay; Eren, Makbule; Ozen, Metehan; MANUEL MARTI, Jose; GARAY, Carlos P.; VANDENPLAS, Yvan; MOYA, Andres; TÜREL, ÖZDENGut microbiota is closely related to acute infectious diarrhea, one of the leading causes of mortality and morbidity in children worldwide. Understanding the dynamics of the recovery from this disease is of clinical interest. This work aims to correlate the dynamics of gut microbiota with the evolution of children who were suffering from acute infectious diarrhea caused by a rotavirus, and their recovery after the administration of a probiotic, Saccharomyces boulardii CNCM I-745. The experiment involved 10 children with acute infectious diarrhea caused by a rotavirus, and six healthy children, all aged between 3 and 4 years. The children who suffered the rotavirus infection received S. boulardii CNCM I-745 twice daily for the first 5 days of the experiment. Fecal samples were collected from each participant at 0, 3, 5, 10, and 30 days after probiotic administration. Microbial composition was characterized by 16S rRNA gene sequencing. Alpha and beta diversity were calculated, along with dynamical analysis based on Taylor's law to assess the temporal stability of the microbiota. All children infected with the rotavirus stopped having diarrhea at day 3 after the intervention. We observed low alpha diversities in the first 5 days (p-value < 0.05, Wilcoxon test), larger at 10 and 30 days after probiotic treatment. Canonical correspondence analysis (CCA) showed differences in the gut microbiota of healthy children and of those who suffered from acute diarrhea in the first days (p-value < 0.05, ADONIS test), but not in the last days of the experiment. Temporal variability was larger in children infected with the rotavirus than in healthy ones. In particular, Gammaproteobacteria class was found to be abundant in children with acute diarrhea. We identified the microbiota transition from a diseased state to a healthy one with time, whose characterization may lead to relevant clinical data. This work highlights the importance of using time series for the study of dysbiosis related to diarrhea.Publication Open Access SAR Evaluation of Disubstituted Tacrine Analogues as Promising Cholinesterase and Carbonic Anhydrase Inhibitors(2019-04-01) ÖKTEN, S; EKIZ, M; TUTAR, A; BÜTÜN, BURCU; Gülçin, İlhami; TOPÇU, GÜLAÇTI; BÜTÜN, BURCU; TOPÇU, GÜLAÇTIBackground: The inhibition of both hydrolysis products of acetylcholine (ACh), Acetylcholinesterase (AChE) and Butyrylcholinesterase (BChE), is essential for successful treatment of Alzhemier patients. Objectives: This study was investigated inhibition potentials of recently synthesized disubstituted tacrines derivatives on going our research against AChE, BChE and carbonic anhydrase cyctosolic (hCA I and H) enzymes to explore the Structure activity relationship (SAR). Methods: Inhibitory activities of tested compounds against AChE and BChE were measured by spectrophotometric method, developed by Ellman et al. Furthermore, the disubstituted tacrines were determined as inhibitors of two physiologically relevant CA isoforms, the cytosolic hCA I and H by an esterase assay method. Results: The silyl, thiomethyl and cyano substituted seven membered hydrocycle tacrines (9, 11 and 14) significantly inhibited AChE, compared with starting compound 3 (6,8-dibromo-2,3,4,5-teytrahydro-1H-cyclohepta[1,2-b] quinoline) and reference compounds, galantamine and tacrine, while methoxy substituted seven membered hydrocycle tacrine derivative 10 showed selective inhibition against BChE (IC50 = 563 nM). Interestingly, disubstituted tacrines displayed higher or parallel inhibition to galantamine. Additionally, all these tacrine analogues were recorded to be powerful inhibitor compounds of the cytosolic isoenzyme hCA I with K-i in the range of 43.81-471.67 nM, as well as a moderate selectivity toward hCA II isoenzyme with K-i in the range from 87.14 to 614.68 nM compared with AZA, as standard. Conclusion: The disubstituted seven membered hydrocycle tacrine analogues 9-12 and 14 may have promising anti Alzhemier drug candidate and dibromo six membered hydrocycle 2 and dibromo seven membered hydrocycle 3 derivatives may be novel hCA I and II enzyme inhibitors.Publication Open Access Clinical Significance of Human Metapneumovirus in Refractory Status Epilepticus and Encephalitis: Case Report and Review of the Literature(2015-01-01) VEHAPOGLU, Aysel; Turel, Ozden; SAHIN, Turkan Uygur; Kutlu, NURETTİN ONUR; ISCAN, Akjn; VEHAPOĞLU TÜRKMEN, AYSEL; TÜREL, ÖZDEN; KUTLU, NURETTİN ONUREncephalitis is a complex neurological disease that is associated with significant morbidity and mortality, and the etiology of the disease is often not identified. Human metapneumovirus (hMPV) is a common cause of upper and lower respiratory tract infections in children. Few reports are available showing possible involvement of hMPV in development of neurologic complications. Here, we describe an infant, the youngest case in literature, with refractory status epilepticus and severe encephalitis in whom hMPV was detected in respiratory samples and review diagnostic workup of patient with encephalitis.Publication Open Access Increasing access to integrated ESKD care as part of universal health coverage(2019-04-01) Harris, David C. H.; DAVIES, Simon J.; Finkelstein, Fredric O.; JHA, Vivekanand; DONNER, Jo-Ann; ABRAHAM, Georgi; Bello, Aminu K.; CASKEY, Fergus J.; GARCIA GARCIA, Guillermo; HARDEN, Paul; KAZANCIOĞLU, RÜMEYZA TURAN; Hemmelgarn, Brenda; JOHNSON, David W.; LEVIN, Nathan W.; Luyckx, Valerie A.; MARTIN, Dominique E.; McCulloch, Mignon I.; MOOSA, Mohammed Rafique; O'Connell, Philip J.; Okpechi, Ikechi G.; PECOITS FILHO, Roberto; SHAH, Kamal D.; SOLA, Laura; Swanepoel, Charles; Tonelli, Marcello; TWAHIR, Ahmed; VAN BIESEN, Wim; VARGHESE, Cherian; Yang, Chih-Wei; ZUNIGA, Carlos; ABU ALFA, Ali K.; ALJUBORI, Harith M.; ALRUKHAIMI, Mona N.; ANDREOLI, Sharon P.; ASHUNTANTANG, Gloria; Bellorin-Font, Ezequiel; BERNIEH, Bassam; IBHAIS, Fuad M.; BLAKE, Peter G.; BROWN, Mark; BROWN, Edwina; BUNNAG, Sakarn; CHAN, Tak Mao; CHEN, Yuqing; CLAURE-DEL GRANADO, Rolando; CLAUS, Stefaan; COLLINS, Allan; COPPO, Rosanna; COUCHOUD, Cecile; CUETO-MANZANO, Alfonso; CULLIS, Brett; DOUTHAT, Walter; DREYER, Gavin; EIAM-ONG, Somchai; EKE, Felicia U.; Feehally, John; GHNAIMAT, Mohammad A.; LEONG, Bak; HASSAN, Mohamed H.; HOU, Fan Fan; JAGER, Kitty; KALANTAR-ZADEH, Kamyar; Levin, Adeera; LIEW, Adrian; McKnight, Marla; TADESSE, Yewondwassesn; Morton, Rachael L.; Muller, Elmi; Murtagh, Fliss E. M.; Naicker, Saraladevi; Nangaku, Masaomi; NIANG, Abdou; OBRADOR, Gregorio T.; OSSAREH, Shahrzad; Perl, Jeffrey; RAHMAN, Muhibur; RASHID, Harun Ur; RICHARDS, Marie; RONDEAU, Eric; SAHAY, Manisha; SALEH, Abdulkarim; SCHNEDITZ, Daniel; TCHOKHONELIDZE, Irma; TESAR, Vladimir; Trask, Michele; TUNGSANGA, Kriang; VACHHARAJANI, Tushar; WALKER, Rachael C.; WALKER, Robert; WERE, Anthony J. O.; YAO, Qiang; YEATES, Karen; YU, Xueqing; ZAKHAROVA, Elena; ZEMCHENKOV, Alexander; Turan Kazancıoğlu, Rümeyza; Zhao, Ming-Hui; KAZANCIOĞLU, RÜMEYZAThe global nephrology community recognizes the need for a cohesive strategy to address the growing problem of end-stage kidney disease (ESKD). In March 2018, the International Society of Nephrology hosted a summit on integrated ESKD care, including 92 individuals from around the globe with diverse expertise and professional backgrounds. The attendees were from 41 countries, including 16 participants from 11 low- and lower-middle-income countries. The purpose was to develop a strategic plan to improve worldwide access to integrated ESKD care, by identifying and prioritizing key activities across 8 themes: (i) estimates of ESKD burden and treatment coverage, (ii) advocacy, (iii) education and training/workforce, (iv) financing/funding models, (v) ethics, (vi) dialysis, (vii) transplantation, and (viii) conservative care. Action plans with prioritized lists of goals, activities, and key deliverables, and an overarching performance framework were developed for each theme. Examples of these key deliverables include improved data availability, integration of core registry measures and analysis to inform development of health care policy; a framework for advocacy; improved and continued stakeholder engagement; improved workforce training; equitable, efficient, and cost-effective funding models; greater understanding and greater application of ethical principles in practice and policy; definition and application of standards for safe and sustainable dialysis treatment and a set of measurable quality parameters; and integration of dialysis, transplantation, and comprehensive conservative care as ESKD treatment options within the context of overall health priorities. Intended users of the action plans include clinicians, patients and their families, scientists, industry partners, government decision makers, and advocacy organizations. Implementation of this integrated and comprehensive plan is intended to improve quality and access to care and thereby reduce serious health-related suffering of adults and children affected by ESKD worldwide.